Celltrion Pharm, Inc. (KOSDAQ: 068760)
South Korea
· Delayed Price · Currency is KRW 59,700
-1,400 (-2.29%)
Dec 20, 2024, 2:57 PM KST
Celltrion Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | 2015 - 2011 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | 2015 - 2011 |
| Operating Revenue | 274,731 | 233,568 | 173,513 | 146,880 | 135,860 | 104,811 | Upgrade
|
| Other Revenue | - | - | 0 | - | -0 | -0 | Upgrade
|
| Revenue | 274,731 | 233,568 | 173,513 | 146,880 | 135,860 | 104,811 | Upgrade
|
| Revenue Growth (YoY) | 53.21% | 34.61% | 18.13% | 8.11% | 29.62% | 40.25% | Upgrade
|
| Cost of Revenue | 193,889 | 160,635 | 111,274 | 106,508 | 77,772 | 62,948 | Upgrade
|
| Gross Profit | 80,842 | 72,933 | 62,239 | 40,372 | 58,088 | 41,863 | Upgrade
|
| Selling, General & Admin | 43,542 | 41,106 | 41,870 | 31,904 | 46,272 | 41,220 | Upgrade
|
| Research & Development | 5,730 | 4,612 | 2,132 | 1,919 | 1,033 | 13,266 | Upgrade
|
| Other Operating Expenses | 1,863 | 1,792 | 1,564 | 1,427 | 1,287 | 1,146 | Upgrade
|
| Operating Expenses | 51,956 | 49,302 | 47,500 | 37,206 | 49,475 | 56,948 | Upgrade
|
| Operating Income | 28,885 | 23,631 | 14,739 | 3,166 | 8,613 | -15,085 | Upgrade
|
| Interest Expense | -4,645 | -4,583 | -5,244 | -5,965 | -5,475 | -8,459 | Upgrade
|
| Interest & Investment Income | 331.11 | 323.72 | 274.92 | 606.53 | 96.78 | 109.28 | Upgrade
|
| Currency Exchange Gain (Loss) | 538.96 | 613.52 | -119.79 | -37.47 | 61.66 | 17.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 67.27 | 168.3 | -40.73 | -124.22 | 12,168 | -32.26 | Upgrade
|
| EBT Excluding Unusual Items | 25,177 | 20,153 | 9,609 | -2,354 | 15,464 | -23,450 | Upgrade
|
| Gain (Loss) on Sale of Assets | -25.64 | -25.64 | -458.61 | -3.36 | - | - | Upgrade
|
| Asset Writedown | - | - | -305.6 | -3,902 | - | - | Upgrade
|
| Pretax Income | 25,152 | 20,128 | 8,845 | -6,260 | 15,464 | -23,450 | Upgrade
|
| Income Tax Expense | -873.97 | -811.83 | 242.68 | 3,129 | -251.21 | -2,344 | Upgrade
|
| Net Income | 26,026 | 20,940 | 8,602 | -9,389 | 15,715 | -21,106 | Upgrade
|
| Net Income to Common | 26,026 | 20,940 | 8,602 | -9,389 | 15,715 | -21,106 | Upgrade
|
| Net Income Growth | 146.80% | 143.42% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 41 | 41 | 41 | 41 | 41 | 35 | Upgrade
|
| Shares Outstanding (Diluted) | 42 | 42 | 42 | 41 | 41 | 35 | Upgrade
|
| Shares Change (YoY) | 0.23% | 0.19% | 0.40% | 1.38% | 18.02% | 33.27% | Upgrade
|
| EPS (Basic) | 628.19 | 505.43 | 207.69 | -226.92 | 385.06 | -610.33 | Upgrade
|
| EPS (Diluted) | 624.77 | 503.33 | 207.20 | -226.94 | 385.06 | -610.33 | Upgrade
|
| EPS Growth | 146.02% | 142.92% | - | - | - | - | Upgrade
|
| Free Cash Flow | -2,181 | -5,731 | -2,633 | 7,106 | -11,242 | -28,294 | Upgrade
|
| Free Cash Flow Per Share | -52.36 | -137.72 | -63.38 | 171.75 | -275.48 | -818.20 | Upgrade
|
| Gross Margin | 29.43% | 31.23% | 35.87% | 27.49% | 42.76% | 39.94% | Upgrade
|
| Operating Margin | 10.51% | 10.12% | 8.49% | 2.16% | 6.34% | -14.39% | Upgrade
|
| Profit Margin | 9.47% | 8.97% | 4.96% | -6.39% | 11.57% | -20.14% | Upgrade
|
| Free Cash Flow Margin | -0.79% | -2.45% | -1.52% | 4.84% | -8.28% | -27.00% | Upgrade
|
| EBITDA | 42,796 | 37,101 | 27,761 | 15,878 | 20,847 | -3,016 | Upgrade
|
| EBITDA Margin | 15.58% | 15.88% | 16.00% | 10.81% | 15.34% | -2.88% | Upgrade
|
| D&A For EBITDA | 13,911 | 13,470 | 13,023 | 12,712 | 12,234 | 12,069 | Upgrade
|
| EBIT | 28,885 | 23,631 | 14,739 | 3,166 | 8,613 | -15,085 | Upgrade
|
| EBIT Margin | 10.51% | 10.12% | 8.49% | 2.16% | 6.34% | -14.39% | Upgrade
|
| Effective Tax Rate | - | - | 2.74% | - | - | - | Upgrade
|
| Advertising Expenses | - | 2,198 | 3,659 | 3,174 | 4,316 | 9,281 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.